intercept
blood
system
ib
platelet
develop
reduc
pathogen
transmiss
risk
transfus
object
studi
comprehens
econom
analysi
costeffect
use
ib
singledonor
apheresi
platelet
ap
randomdonor
pool
platelet
concentr
pc
versu
ap
pc
without
ib
rhe
unit
state
patient
popul
platelet
commonli
transfus
method
data
use
analysi
summar
exist
publish
sourc
primarili
index
medlin
data
file
baxter
healthcar
corpor
chicago
illinoi
ceru
corpor
concord
california
literaturebas
decisionanalyt
model
develop
assess
econom
cost
clinic
outcom
associ
use
ap
pc
treat
ib
sever
condit
procedur
account
consider
proport
platelet
usag
unit
state
acut
lymphocyt
leukemia
nonhodgkin
lymphoma
coronari
arteri
bypass
graft
hip
arthroplasti
risk
infect
hiv
hepat
c
viru
hcv
hepat
b
viru
human
tcell
lymphotrop
viru
type
bacteri
agent
incorpor
model
possibl
benefit
reduct
risk
emerg
hcvlike
pathogen
elimin
need
gamma
irradi
explor
sensit
analys
result
increment
cost
per
qualityadjust
lifeyear
gain
use
ap
ib
versu
untreat
ap
rang
without
bacteinclus
emerg
hcvlike
viru
elimin
need
gamma
irradi
improv
costeffect
rang
ap
without
bacteri
test
ap
bacteri
test
pc
model
like
affect
mortal
bacteri
contamin
ib
effect
platelet
util
inclus
potenti
benefit
ie
gamma
irradi
andor
emerg
hcvlike
viru
model
rel
insensit
chang
ib
price
viral
transmiss
risk
conclus
costeffect
pathogen
inactiv
via
ib
platelet
compar
accept
blood
safeti
intervent
eg
nucleic
acid
amplif
technolog
ib
platelet
may
consid
desir
strategi
increas
safeti
platelet
transfus
potenti
insur
threat
emerg
pathogen
qin
ther
safeti
blood
transfus
major
concern
health
care
polici
maker
especi
face
risk
transmiss
infecti
bloodborn
pathogen
hiv
hepat
c
viru
hcv
hepat
b
viru
hbv
human
tcell
lymphotrop
viru
type
htlvi
bacteria
measur
reduc
transfusiontransmiss
risk
includ
donor
screeningeduc
strategi
laboratori
test
eg
nucleic
acid
amplif
technolog
nat
hiv
antigen
test
preoper
autolog
donat
limit
donor
exposur
use
singledonor
apheresi
platelet
ap
leukocyt
reduct
benefit
measur
realiz
form
reduct
risk
transmiss
infecti
pathogen
howev
measur
limit
remain
residu
risk
attribut
windowperiod
instanc
residu
risk
transmiss
estim
per
ooo
unit
hiv
per
ooo
unit
hcv
depend
donor
statu
perhap
greater
concern
challeng
protect
blood
compon
particularli
platelet
bacteri
platelet
store
room
temperatur
offer
nutrientrich
environ
bacteria
multipli
although
laboratori
test
detect
bacteri
contamin
platelet
exist
routin
perform
overal
incid
transfusionrel
sepsi
tr
due
bacteri
contamin
platelet
rel
high
recent
surveil
studi
death
rate
due
bacteri
contamin
platelet
report
rang
per
million
unit
ap
per
million
unit
randomdonor
pool
platelet
concentr
pc
pathogen
inactiv
treatment
intercept
blood
system
ib
platelet
new
technolog
aim
enhanc
safeti
platelet
transfus
ib
inactiv
broad
spectrum
virus
bacteria
parasit
present
platelet
compon
target
dna
rna
pathogen
form
irrevers
crosslink
thu
prevent
pathogen
replic
process
effect
pathogen
affect
vitro
vivo
platelet
requir
genet
materi
function
use
treat
platelet
may
substanti
reduc
risk
pathogen
transmiss
risk
tr
due
bacteri
contamin
furthermor
use
platelet
process
pathogen
inactiv
treatment
may
protect
futur
platelet
recipi
emerg
pathogen
donor
screen
may
ineffect
test
concomit
use
blood
product
red
blood
cell
plasma
often
administ
platelet
transfus
risk
entir
elimin
howev
ongo
advanc
clinic
investig
pathogen
inactiv
treatment
red
blood
cell
face
decis
whether
adopt
new
treatment
strategi
ib
health
care
polici
maker
must
balanc
compet
interest
public
safeti
effici
use
health
care
resourc
although
improv
overal
safeti
platelet
transfus
may
result
use
ib
platelet
benefit
system
presum
would
achiev
extra
cost
costeffect
analysisassess
net
chang
cost
outcom
medic
interventionsha
becom
accept
method
comparison
medic
intervent
guidanc
decis
effici
use
health
care
resourc
therefor
conduct
comprehens
econom
analysi
costeffect
use
ib
platelet
ap
pc
versu
untreat
ap
pc
unit
state
patient
popul
platelet
commonli
transfus
data
use
analysi
summar
exist
publish
sourc
primarili
index
medlin
data
file
baxter
healthcar
corpor
chicago
illinoi
ceru
corpor
concord
california
literaturebas
decisionanalyt
model
develop
assess
econom
cost
clinic
outcom
associ
use
ap
pc
treat
ib
platelet
ap
ib
pc
ib
current
analysi
expand
previ
tabl
decis
tree
figur
construct
patient
receiv
ap
ib
versu
ap
without
ib
ident
decis
tree
construct
analysi
pc
ib
versu
pc
without
ib
baselin
model
includ
current
risk
infect
hiv
hcv
hbv
bacteri
agent
plateletdonor
exposur
model
simul
subsequ
transfusionrel
event
outcom
well
event
would
occur
natur
patient
may
experi
morbid
mortal
due
sever
caus
eg
underli
diseas
transfusionrel
complic
gener
mortal
popul
age
sex
clinic
outcom
result
underli
diseas
transfusionrel
complic
assign
treatment
cost
util
life
expect
estim
calcul
use
declin
exponenti
approxim
life
expect
took
consider
compet
mortal
diseasespecif
natur
occur
caus
excess
annual
mortal
rate
qali
weight
util
studi
popul
present
tabl
direct
medic
cost
attribut
use
ap
ib
pc
ib
well
present
valu
futur
cost
attribut
treat
transfusionrel
complic
incorpor
baselin
model
indirect
cost
eg
work
product
loss
consid
project
econom
cost
health
benefit
futur
year
discount
per
annum
consist
current
practic
model
estim
increment
cost
health
benefit
ie
qali
use
ap
ib
pc
ib
versu
untreat
ap
pc
respect
increment
costeffect
ratio
icer
calcul
costaplb
costap
qalyapb
qali
repres
case
increment
cost
per
qali
gain
use
ap
ib
versu
untreat
ap
risk
acquir
transfusiontransmit
pathogen
deriv
publish
data
tabl
ii
f
baselin
valu
weight
mean
risk
firsttim
donor
repeat
donor
use
recent
state
viral
transmiss
risk
firsttim
donor
time
greater
repeat
donor
addit
estim
donat
firsttim
therefor
risk
report
studi
weight
respect
tabl
ii
subsequ
outcom
transfusionacquir
hiv
infect
aidsrel
complex
time
symptom
onset
year
transfusionacquir
hcv
hbv
outcom
categor
group
chronic
hepat
cirrhosi
hepatocellular
carcinoma
hcc
fulmin
hepat
chronic
hepat
fulmin
hepat
assum
occur
year
transfus
receiv
cirrhosi
hcc
onset
assum
occur
year
transfus
adult
tcell
leukemiallymphoma
htlvlassoci
myelopathi
subsequ
outcom
transfusionacquir
htlvi
time
symptom
onset
year
probabl
develop
diseas
outcom
estim
literatur
tabl
qualityoflif
impact
mortal
estim
attribut
subsequ
outcom
transfusionacquir
sequela
tabl
iii
cumul
death
rate
use
reflect
impact
bacteri
contamin
sever
studi
report
death
rate
per
million
due
bacteriacontamin
blood
death
rate
per
million
bacteri
contamin
calcul
weight
mean
sampl
per
million
ap
per
million
pc
tabl
bacon
exclud
calcul
risk
underestim
well
recogn
larg
sampl
size
would
bia
weight
mean
howev
data
use
low
bound
sensit
analysi
gener
conserv
estim
death
per
million
ap
pc
data
studi
john
serv
high
bound
sensit
analysi
death
per
million
ap
pc
respect
expect
plan
introduct
bacteri
screen
ap
unit
state
near
futur
reduc
risk
bacteri
contamin
tr
mortal
altern
baselin
scenario
develop
assum
bacteri
screen
wide
use
ap
replac
ib
bacteri
test
assum
cost
per
dose
platelet
reduc
mortal
bacteri
contamin
ie
death
per
million
remain
rang
ie
death
per
million
remain
univari
scenario
multivari
sensit
analys
conduct
determin
robust
model
result
identifi
variabl
contribut
model
result
identifi
import
model
uncertainti
univari
analysi
model
variabl
vari
one
one
conduct
transfusiontransmiss
risk
cost
treatment
transfusionrel
sequela
cost
ib
probabl
diseas
outcom
addit
impact
elimin
need
gamma
irradi
assess
gamma
irradi
lymphocyt
inactiv
method
red
blood
cell
platelet
commonli
use
reduc
risk
graftversushost
diseas
gvifid
gvhd
occur
viabl
lymphocyt
transfus
blood
blood
compon
engraft
multipli
react
tissu
recipi
ib
platelet
target
dna
rna
inactiv
lymphocyt
potenti
elimin
need
gamma
assess
impact
scenario
gamma
irradi
process
cost
longer
requir
use
ap
ib
pc
ib
includ
sensit
analysi
anoth
potenti
benefit
pathogen
inactiv
via
ib
platelet
abil
reduc
risk
transmiss
emerg
pathogen
new
pathogen
continu
discov
everi
year
new
diseas
microorgan
identifi
last
year
includ
hivaid
everi
new
pathogen
discov
time
lag
pathogen
discoveri
widespread
avail
effect
test
even
effect
test
develop
exist
possibl
pathogen
may
detect
eg
small
pathogenload
count
case
hcv
american
infect
via
blood
transfus
primarili
approv
first
hcv
blood
assess
impact
use
ap
ib
pc
ib
hypothet
scenario
involv
hcvlike
pathogen
incorpor
sensit
analys
risk
acquir
emerg
pathogen
assum
per
unit
similar
hcv
first
subsequ
outcom
treatment
cost
base
hcv
baselin
model
addit
consider
use
ib
platelet
could
increas
platelet
use
loss
pathogen
inactiv
process
reduct
platelet
recoveri
assess
impact
baselin
model
assess
scenario
platelet
use
increas
rang
test
sensit
analysi
final
multivari
sensit
analysi
variabl
provid
rang
tabl
ii
iv
conduct
via
mont
carlo
simul
probabilist
sensit
analysi
entail
conduct
iter
model
use
iter
random
set
model
paramet
valu
select
assum
paramet
distribut
base
rang
valu
found
literatur
see
tabl
iiiv
paramet
distribut
unavail
triangular
distribut
use
presum
likeliest
valu
ie
baselin
valu
fell
minimum
maximum
valu
assum
baselin
iter
expect
cost
outcom
use
calcul
icer
costeffect
accept
gener
illustr
confid
may
infer
use
ap
ib
pc
ib
would
costeffect
rang
threshold
accept
baselin
result
us
dollar
present
tabl
v
ib
also
costeffect
pediatr
patient
popul
studi
versu
adult
patient
popul
ap
pc
univari
sensit
analys
indic
model
result
sensit
individu
chang
valu
sever
paramet
specif
follow
paramet
like
affect
model
result
mortal
due
bacteri
contamin
ib
effect
platelet
util
inclus
potenti
benefit
ie
gamma
irradi
andor
emerg
hcvlike
viru
correspond
icer
differ
scenario
present
tabl
v
tabl
vi
contrast
find
chang
ib
price
transmiss
risk
hiv
hbv
hcv
within
rang
test
significantli
alter
model
result
icer
highli
sensit
death
rate
due
bacteri
contamin
death
rate
increas
death
per
million
ap
pc
death
death
per
million
ap
pc
respect
increment
cost
per
qali
decreas
ap
ib
versu
ap
pc
ib
versu
pc
among
pediatr
patient
mortal
rate
increas
death
per
million
death
per
million
bacteri
screen
ap
increment
cost
per
qali
decreas
ap
ib
versu
ap
among
pediatr
patient
similar
trend
found
patient
popul
increas
platelet
use
due
ib
treatment
also
increas
icer
icer
increas
platelet
yield
reduct
rate
rais
ap
pc
patient
popul
convers
ratio
decreas
platelet
yield
reduct
rate
decreas
elimin
need
gamma
irradi
reduc
icer
ap
pc
nhl
patient
scenario
assess
patient
undergo
cabg
hip
arthroplasti
surgeri
experi
patient
typic
requir
irradi
blood
compon
emerg
highli
preval
hcvlike
pathogen
introduc
model
cost
per
qali
ap
ib
pc
ib
decreas
dramat
patient
popul
ap
ib
icer
declin
rang
per
qali
use
baselin
scenario
rang
per
qali
use
baselin
scenario
pc
ib
icer
decreas
rang
per
qali
expect
consider
combin
scenario
high
bound
death
rate
bacteri
contamin
use
gamma
irradi
longer
requir
emerg
hcvlike
pathogen
introduc
result
dramat
lower
icer
compar
baselin
scenario
maximum
observ
icer
less
per
qali
ap
ib
less
per
qali
pc
ib
probabilist
sensit
analysi
indic
result
sensit
simultan
chang
multipl
paramet
list
rang
tabl
ii
iv
instanc
pediatr
patient
result
mont
carlo
simul
indic
icer
ap
ib
versu
untreat
ap
less
million
without
bacteri
test
million
bacteri
test
model
run
less
million
without
bacteri
test
million
bacteri
test
model
run
patient
popul
icer
ap
ib
versu
untreat
ap
less
million
million
hip
arthroplasti
less
million
million
cabg
less
million
million
nhl
model
run
less
million
hip
arthroplasti
million
cabg
million
nhl
model
run
discuss
current
analysi
provid
comprehens
econom
assess
ap
pc
treat
ib
platelet
decisionanalyt
model
account
morbid
mortal
associ
patient
underli
condit
well
transfusionrel
complic
model
use
recent
publish
pathogentransmiss
risk
subsequ
transfusionrel
outcom
treatment
cost
assess
health
benefit
costeffect
ib
platelet
patient
commonli
receiv
platelet
transfus
model
observ
cost
transfus
ap
ib
versu
untreat
ap
rang
pediatr
nhl
qali
save
bacteri
screen
ap
reduc
mortal
rate
bacteri
contamin
make
increment
cost
per
qali
ib
treatment
excess
million
patient
popul
baselin
correspond
figur
transfus
pc
ib
versu
untreat
pc
rang
pediatr
nhl
although
seemingli
high
compar
threshold
ratio
commonli
use
field
medicin
per
icer
compar
previous
report
costeffect
find
accept
blood
safeti
intervent
instanc
recent
studi
jackson
et
show
icer
wholeblood
nat
hiv
hcv
hbv
rang
million
per
qali
save
stone
et
al
also
found
blood
safeti
intervent
median
icer
per
qali
valu
rang
costsav
million
per
qali
graphic
summari
result
publish
costeffect
analys
safeti
intervent
figur
indic
icer
blood
safeti
injuri
prevent
measur
domin
ratio
higher
per
find
suggest
ib
associ
icer
compar
exist
propos
blood
safeti
intervent
highli
valu
public
polici
maker
risk
transfusiontransmit
infect
due
current
screen
pathogen
rel
small
continu
addit
new
test
nat
suggest
safeti
still
paramount
polici
decisionmak
process
thu
higher
costeffect
threshold
may
appli
evalu
new
blood
safeti
technolog
result
present
analysi
indic
ib
platelet
rel
costeffect
pediatr
patient
orthoped
patient
follow
cabg
nhl
patient
overal
find
reflect
favor
shortterm
prognosi
pediatr
orthoped
patient
mortal
qualiti
life
treatment
rel
similar
expect
normal
popul
anticip
life
expect
pediatr
patient
also
greater
due
younger
age
time
transfus
contrast
nhl
cabg
patient
popul
associ
rel
higher
firstyear
posttreat
mortal
rate
reduc
potenti
benefit
avoid
transfusionrel
infect
sensit
analysi
indic
model
result
significantli
affect
chang
viraltransmiss
risk
test
current
perform
benefit
ib
platelet
driven
tr
mortal
due
bacteri
contamin
platelet
current
bacteri
contamin
remain
frequent
infecti
complic
associ
platelet
transfus
although
adopt
bacteri
test
unit
state
near
futur
expect
reduc
risk
bacteri
contamin
tr
mortal
residu
risk
remain
due
limit
bacteri
test
system
circumst
benefit
ib
would
actual
substanti
reduc
shown
baselin
scenario
howev
concurr
use
pathogen
inactiv
bacteri
test
unlik
gener
use
ib
would
probabl
omit
need
bacteri
test
mortal
bacteri
contamin
directli
model
current
analysi
without
consider
nonfat
outcom
rational
approach
follow
vari
clinic
definit
transfus
reaction
led
number
differ
report
tr
incid
incid
sepsi
mildsever
septic
reaction
bacteri
contamin
bacteriarel
event
transfus
reaction
lack
clear
consensu
true
incidencehowev
cumul
mortal
rate
per
million
unit
consist
use
literatur
estim
impact
tr
rate
nonfat
reaction
often
underestim
underrecognit
underreport
j
econom
impact
septic
reaction
mild
sever
due
bacteri
contamin
minim
may
neglect
due
rare
occurr
focus
critic
effect
trspatient
mortalitymay
simplifi
well
clarifi
model
mortal
rate
due
bacteri
contamin
report
sever
wellknown
surveil
studi
unit
state
found
cumul
death
rate
per
million
ap
pc
respect
base
data
year
howev
surveil
studi
eg
us
food
drug
administr
surveil
bacteri
safeti
fatal
incid
rate
underestim
limit
surveil
studi
methodolog
studi
conduct
match
casecontrol
studi
design
report
cumul
death
rate
pc
ap
ci
ci
per
million
studi
john
hopkin
reveal
cumul
death
rate
period
per
million
ap
per
million
pc
rate
much
higher
surveil
may
reflect
aggress
abil
hospitalbas
studi
detect
report
case
consid
limit
strength
studi
deathpermillion
rate
bacteri
contamin
conserv
calcul
studi
weight
averag
sampl
size
per
million
ap
per
million
pc
bacon
exclud
calcul
underestim
well
recogn
larg
sampl
size
would
bia
weight
averag
ib
platelet
design
reduc
risk
transmiss
known
pathogen
eg
hiv
hcv
hbv
bacteri
agent
million
unit
platelet
transfus
annual
unit
state
europ
japan
ie
hiv
hcv
hbv
infect
death
due
bacteri
contamin
could
avoid
howev
system
also
potenti
reduc
risk
associ
emerg
pathogen
donor
screen
strategi
laboratori
test
current
exist
therefor
studi
conserv
adopt
hypothet
hcvlike
pathogen
assess
potenti
benefit
ib
prevent
reduct
infect
risk
emerg
pathogen
unlik
hivlik
virus
hcv
infect
result
sever
clinic
ill
remain
asymptomat
gener
conserv
estim
viru
select
mimic
emerg
viru
scenario
result
sensit
analysi
indic
ib
would
much
costeffect
patient
popul
potenti
benefit
includ
model
expect
scenario
multipl
new
pathogen
encount
would
improv
costeffect
ib
one
import
trend
health
care
increas
emphasi
diseas
prevent
potenti
ib
prevent
transmiss
emerg
pathogen
caus
agent
sever
acut
respiratori
west
nile
may
increas
safeti
platelet
transfus
ib
may
also
help
avoid
otherwis
inevit
addit
new
screen
test
studi
intend
gener
conserv
result
exampl
studi
includ
potenti
benefit
ib
extend
shelflif
platelet
concentr
although
report
principl
pathogen
inactiv
may
extend
storag
time
platelet
concentr
day
current
day
addit
indirect
cost
consid
attribut
worker
product
loss
due
prematur
death
litig
cost
stem
pathogen
transmiss
sequela
inclus
potenti
benefit
would
result
favor
result
ap
ib
pc
ib
critic
assumpt
current
analysi
ib
platelet
effect
prevent
transmiss
pathogen
use
modell
associ
advers
health
effect
clinic
trial
unit
state
europ
assess
efficaci
safeti
ib
platelet
excess
treatmentrel
advers
event
detect
patient
receiv
treat
platelet
compon
howev
inher
assum
benefit
use
platelet
treat
pathogen
inactiv
process
level
uncertainti
benefit
gain
use
pathogeninactiv
platelet
may
offset
incid
unanticip
advers
event
treatmentrel
hazard
costeffect
pathogen
inactiv
via
ib
platelet
compar
accept
blood
safeti
intervent
eg
nat
test
hiv
antigen
test
solventdeterg
treatment
major
advantag
ib
prevent
viru
transmiss
bacteri
contamin
emerg
pathogen
perhap
avoid
futur
screen
test
well
blood
bank
hospit
institut
administ
platelet
transfus
could
consid
ib
platelet
desir
strategi
increas
safeti
platelet
transfus
potenti
insur
threat
emerg
pathogen
